2024-514058-59-00招募中2 期
A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOint INhibiTor (anti PD1/PDL1).
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 49
- 试验地点
- 2
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
Assess the progression free survival (PFS) of cabozantinib in patients pretreated with one immunocheckpoint inhibitor (CPI) in monotherapy or in combination.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Signed written informed consent
- •The required values at baseline are as follows: Absolute neutrophil count >1.5 x 10^9 /L, Platelet count > 100 x 10^9 /L, Haemoglobin > 9g/dl, Total bilirubin < 1.5 upper limit of normal (ULN), AST, ALT<2.5 ULN in patients without liver metastases <5 ULN in patients with liver metastases, serum creatinine < 2.0 mg/dl, amylase and lipase <1.5 ULN
- •Female subjects of childbearing potential must not be pregnant at screening
- •One previous anticancer treatment with a PD1/PDL1 inhibitor, as monotherapy or in combination with an angiogenesis inhibitor or anti CTLA 4, in both setting first line or adjuvant ( in this case patient having recurrence during the adjuvant treatment or within 6 months after therapy with PD1-PD-L1 therapy)
- •Age >=18 years
- •Patients with histological diagnosis of predominant clear cells renal cell carcinoma
- •Measurable disease (as per RECIST 1.1 criteria) with documented radiological progression
- •Fertile women (<2 years after last menstruation) and men of childbearing potential must use effective methods of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilisation) during the study and for 4 months after the last dose of study treatment
- •All sites of disease including brain metastases (non symptomatic)
- •Karnofsky performance status >= 70%
- •Life expectancy greater than 3 months
排除标准
- •Major surgical procedure within 28 days prior to study treatment start
- •Uncontrolled hypertension (>= 160 mmHg systolic and/or 90 mmHg diastolic) while receiving chronic medication
- •Inability to swallow tablets or capsules
- •Female subject who is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum ß-human chorionic gonadotropin (ßhCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women
- •Known history of human immunodeficiency virus (HIV) infection, active hepatitis B, or active hepatitis C
- •Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
- •Other malignancies within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix, meningiomas)
- •Clinically significant cardiovascular disease, for example cerebrovascular accidents (<6 months), myocardial infarction (<6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication
- •Recent (within the 30 days prior to randomisation) treatment with another investigational drug or participation in another investigational study
- •Symptomatic brain metastasis
- •History of other disease, metabolic dysfunction, physical examination finding or clinical laboratory finding giving reasonable suspicion of a disease condition that contraindicates use of an investigational drug or patient at high risk from treatment complications
- •or INR and PTT >1.5 times the Upper Normal Limit of the institution (patient who are being therapeutically anticoagulated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists).For patients on warfarin, close monitoring of at least weekly evaluations will be performed, until INR is stable based on a measurement at pre-dose, as defined by the local standard of care
- •Previous or concomitant radiotherapy in the lesion parameter of disease
- •Previous radiotherapy or other locoregional antitumoral treatment performed within 21 days before the study recruitment
结局指标
主要结局
Progression Free Survival (PFS)
Progression Free Survival (PFS)
次要结局
- Overall Survival (OS)
- Objective Response Rates (ORR)
- Safety profile of the drug
研究者
Oncologia genitourinaria
Scientific
Fondazione IRCCS Istituto Nazionale Dei Tumori
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.2024-511292-15-00Grupo Espanol De Tumores Neuroendocrinos41
招募中
3 期
Study of Cabozantinib in Combination With Atezolizumab compared to Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer2024-516481-11-00Exelixis Inc.203
尚未招募
2 期
SPARTANA : Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal carcinoma.2024-516005-23-00Centre Hospitalier Regional Universitaire34
招募中
2 期
Phase 2 Futibatinib in Combination with PD-1 Antibody-based Standard of Care in Solid Tumors2023-507516-12-00Taiho Oncology Inc.15
招募中
3 期
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Crohn's Disease2023-509618-12-00AbbVie Deutschland GmbH & Co. KG39